Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2026-06-15 @ 11:08 AM
Study NCT ID:
NCT02257567
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2014-10-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma | View |
Keywords: